Literature DB >> 9130987

Stromal tumors of the jejunum and ileum: a clinicopathologic study of 39 cases.

J A Brainard1, J R Goldblum.   

Abstract

Recently, cell size, cell density, and growth pattern were found to be reliable histologic parameters in separating benign from malignant duodenal stromal tumors. However, there are few data on the histologic features and important prognostic parameters of stromal tumors from other parts of the small bowel. Thus, we studied the clinical and pathologic features of 39 stromal tumors of the jejunum and ileum to determine which parameters would be most useful in distinguishing a benign from a malignant tumor. In all cases, the following histologic parameters were recorded: (a) predominant growth pattern (organoid, fascicular, solid, or mixed), (b) cellularity (low or high), (c) predominant cell type (spindled, epithelioid, or mixed), (d) nuclear pleomorphism (minimal, moderate, or severe), (e) the presence or absence of tumor cell necrosis, (f) the presence or absence of mucosal infiltration, (g) the presence or absence of skeinoid fibers, and (h) the number of mitotic figures per 50 high-power microscopic fields (HPF). Clinical follow-up was obtained in all cases, and the patients were considered to have suffered an adverse outcome if they developed metastatic disease or died as a complication of their tumor. In the absence of these features, patients were not considered to have suffered an adverse outcome. Twenty-five patients suffered an adverse outcome. Twenty-one patients died of disease from 1 month to 9 years (median: 2 years). One patient died at 4 days because of postoperative complications. Three patients were alive with metastatic disease at 6 months, 6 years, and 7 years. Twenty-four of these 25 patients developed metastatic disease, most commonly to the liver. Fourteen patients did not suffer an adverse outcome. Eleven patients were alive without disease from 2 to 11 years (median: 3 years), and three patients died of unrelated causes at 1, 1, and 3 years. Although there was some overlap in features between clinically benign and malignant tumors, features that were significantly associated with an adverse outcome included tumor size > 5 cm, mitotic counts > 5 mitotic figures per 50 HPF, high cellularity, the absence of a predominant organoid growth pattern, the absence of skeinoid fibers, the presence of severe nuclear pleomorphism, and the presence of mucosal infiltration and tumor cell necrosis (p < 0.05 using the chi-square and Fisher's exact tests). Features that were significantly associated with decreased survival included tumor size > 5 cm, mitotic counts > 5 mitotic figures per 50 HPF, high cellularity, the absence of skeinoid fibers, and the presence of tumor cell necrosis (p < 0.05 using the Mantel-Haenszel log-rank test). Given the fact that there is some overlap in these features between clinically benign and malignant tumors, a multiparametric analysis using the above features is the most effective way of predicting clinical behavior.

Entities:  

Mesh:

Year:  1997        PMID: 9130987     DOI: 10.1097/00000478-199704000-00006

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  20 in total

1.  Reactive Nodular Fibrous Pseudotumor Presenting as a Huge Intra abdominal Mass after Abdominal Surgery: a Case Report.

Authors:  Birgul Ciftci; Enver Vardar; Funda Tasli; Savas Yakan; Erdinc Top; Mehmet Yildirim
Journal:  Iran J Pathol       Date:  2015

2.  Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal.

Authors:  L G Kindblom; H E Remotti; F Aldenborg; J M Meis-Kindblom
Journal:  Am J Pathol       Date:  1998-05       Impact factor: 4.307

3.  Gastrointestinal stromal tumor with skeinoid fibers: an unusual presentation.

Authors:  A Trecca; F Ortica; G Marinozzi; R Borghini; C Camponi; A Baldi
Journal:  Tech Coloproctol       Date:  2018-11-24       Impact factor: 3.781

4.  Perforated Meckel's diverticulum presenting as a gastrointestinal stromal tumor: a case report.

Authors:  Martina Hager; Hans Maier; Martin Eberwein; Paul Klingler; Christian Kolbitsch; Werner Tiefenthaler; Gregor Mikuz; Patrizia Lucia Moser
Journal:  J Gastrointest Surg       Date:  2005 Jul-Aug       Impact factor: 3.452

5.  Gastrointestinal stromal tumors: a clinicopathological and immunohistochemical study of 121 cases.

Authors:  Mukul Vij; Vinita Agrawal; Ashok Kumar; Rakesh Pandey
Journal:  Indian J Gastroenterol       Date:  2011-01-11

6.  Endoscopic features of intestinal smooth muscle tumor in a child with AIDS.

Authors:  Z L Molle; P Bornemann; N Desai; E Clarin; V Anderson; S S Rabinowitz
Journal:  Dig Dis Sci       Date:  1999-05       Impact factor: 3.199

7.  MDCT and clinicopathological features of small bowel gastrointestinal stromal tumours in 102 patients: a single institute experience.

Authors:  A D Baheti; A B Shinagare; A C O'Neill; K M Krajewski; J L Hornick; S George; N H Ramaiya; S H Tirumani
Journal:  Br J Radiol       Date:  2015-06-25       Impact factor: 3.039

8.  Prognostic factors and outcome of resected patients with gastrointestinal stromal tumors of small intestine.

Authors:  Rong Fan; Jie Zhong; Zhen-ting Wang; Li-fen Yu; Yong-hua Tang; Wei-guo Hu; Yan-bo Zhu; Xiao-long Jin
Journal:  Med Oncol       Date:  2010-10-08       Impact factor: 3.064

Review 9.  [Gastrointestinal stromal tumors. A morphologic and molecular genetic independent tumor entity with new therapeutic perspectives].

Authors:  G Mechtersheimer; T Lehnert; R Penzel; S Joos; G Egerer; H F Otto
Journal:  Pathologe       Date:  2003-03-21       Impact factor: 1.011

10.  Back to the start: Evaluation of prognostic markers in gastrointestinal stromal tumors.

Authors:  Eckhard Klieser; Maximilian Pichelstorfer; Denis Weyland; Ralf Kemmerling; Stefan Swierczynski; Adam Dinnewitzer; Tarkan Jäger; Tobias Kiesslich; Daniel Neureiter; Romana Illig
Journal:  Mol Clin Oncol       Date:  2016-03-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.